Carregant...
Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites
Production of glycoconjugate vaccines involves the chemical conjugation of glycans to an immunogenic carrier protein such as Cross-Reactive-Material-197 (CRM(197)). Instead of using glycans from natural sources recent vaccine development has been focusing on the use of synthetically defined minimal...
Guardat en:
| Publicat a: | Sci Rep |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4740906/ https://ncbi.nlm.nih.gov/pubmed/26841683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep20488 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|